ID   RIPK4_HUMAN             Reviewed;         832 AA.
AC   P57078; Q96KH0;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 1.
DT   12-OCT-2022, entry version 188.
DE   RecName: Full=Receptor-interacting serine/threonine-protein kinase 4;
DE            EC=2.7.11.1;
DE   AltName: Full=Ankyrin repeat domain-containing protein 3;
DE   AltName: Full=PKC-delta-interacting protein kinase;
GN   Name=RIPK4; Synonyms=ANKRD3, DIK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Fetal kidney, and Fetal lung;
RA   Shimizu N., Kudoh J., Shibuya K.;
RL   Submitted (AUG-2000) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10830953; DOI=10.1038/35012518;
RA   Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T., Park H.-S.,
RA   Toyoda A., Ishii K., Totoki Y., Choi D.-K., Groner Y., Soeda E., Ohki M.,
RA   Takagi T., Sakaki Y., Taudien S., Blechschmidt K., Polley A., Menzel U.,
RA   Delabar J., Kumpf K., Lehmann R., Patterson D., Reichwald K., Rump A.,
RA   Schillhabel M., Schudy A., Zimmermann W., Rosenthal A., Kudoh J.,
RA   Shibuya K., Kawasaki K., Asakawa S., Shintani A., Sasaki T., Nagamine K.,
RA   Mitsuyama S., Antonarakis S.E., Minoshima S., Shimizu N., Nordsiek G.,
RA   Hornischer K., Brandt P., Scharfe M., Schoen O., Desario A., Reichelt J.,
RA   Kauer G., Bloecker H., Ramser J., Beck A., Klages S., Hennig S.,
RA   Riesselmann L., Dagand E., Wehrmeyer S., Borzym K., Gardiner K.,
RA   Nizetic D., Francis F., Lehrach H., Reinhardt R., Yaspo M.-L.;
RT   "The DNA sequence of human chromosome 21.";
RL   Nature 405:311-319(2000).
RN   [3]
RP   PROTEOLYTIC CLEAVAGE AT ASP-388 AND ASP-426, INTERACTION WITH TRAF1; TRAF2;
RP   TRAF3 AND TRAF5, AND FUNCTION.
RX   PubMed=12446564; DOI=10.1093/embo-reports/kvf236;
RA   Meylan E., Martinon F., Thome M., Gschwendt M., Tschopp J.;
RT   "RIP4 (DIK/PKK), a novel member of the RIP kinase family, activates NF-
RT   kappa B and is processed during apoptosis.";
RL   EMBO Rep. 3:1201-1208(2002).
RN   [4]
RP   UBIQUITINATION AT LYS-51 AND LYS-145, UBIQUITINATION BY BIRC2/C-IAP1 AND
RP   BIRC3/C-IAP2, AND INTERACTION WITH BIRC2/C-IAP1; BIRC3/C-IAP2 AND
RP   XIAP/BIRC4.
RX   PubMed=21931591; DOI=10.1371/journal.pone.0022356;
RA   Bertrand M.J., Lippens S., Staes A., Gilbert B., Roelandt R., De Medts J.,
RA   Gevaert K., Declercq W., Vandenabeele P.;
RT   "cIAP1/2 are direct E3 ligases conjugating diverse types of ubiquitin
RT   chains to receptor interacting proteins kinases 1 to 4 (RIP1-4).";
RL   PLoS ONE 6:E22356-E22356(2011).
RN   [5]
RP   FUNCTION, AND VARIANT BPS ASN-81.
RX   PubMed=22197488; DOI=10.1016/j.ajhg.2011.11.013;
RA   Mitchell K., O'Sullivan J., Missero C., Blair E., Richardson R.,
RA   Anderson B., Antonini D., Murray J.C., Shanske A.L., Schutte B.C.,
RA   Romano R.A., Sinha S., Bhaskar S.S., Black G.C., Dixon J., Dixon M.J.;
RT   "Exome sequence identifies RIPK4 as the Bartsocas-Papas syndrome locus.";
RL   Am. J. Hum. Genet. 90:69-75(2012).
RN   [6]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-462; MET-463; TYR-562; HIS-669 AND
RP   SER-749.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [7]
RP   VARIANTS BPS ASN-121 AND ILE-184, AND CHARACTERIZATION OF VARIANTS BPS
RP   ASN-121 AND ILE-184.
RX   PubMed=22197489; DOI=10.1016/j.ajhg.2011.11.014;
RA   Kalay E., Sezgin O., Chellappa V., Mutlu M., Morsy H., Kayserili H.,
RA   Kreiger E., Cansu A., Toraman B., Abdalla E.M., Aslan Y., Pillai S.,
RA   Akarsu N.A.;
RT   "Mutations in RIPK4 cause the autosomal-recessive form of popliteal
RT   pterygium syndrome.";
RL   Am. J. Hum. Genet. 90:76-85(2012).
RN   [8]
RP   INVOLVEMENT IN CHANDS, AND VARIANT CHANDS ASP-163.
RX   PubMed=23610050; DOI=10.1002/ajmg.a.35913;
RA   Gripp K.W., Ennis S., Napoli J.;
RT   "Exome analysis in clinical practice: expanding the phenotype of Bartsocas-
RT   Papas syndrome.";
RL   Am. J. Med. Genet. A 161A:1058-1063(2013).
RN   [9]
RP   INVOLVEMENT IN CHANDS, VARIANT CHANDS LYS-284, AND TISSUE SPECIFICITY.
RX   PubMed=26129644; DOI=10.1002/ajmg.a.37233;
RA   Gollasch B., Basmanav F.B., Nanda A., Fritz G., Mahmoudi H., Thiele H.,
RA   Wehner M., Wolf S., Altmueller J., Nuernberg P., Frank J., Betz R.C.;
RT   "Identification of a novel mutation in RIPK4 in a kindred with phenotypic
RT   features of Bartsocas-Papas and CHAND syndromes.";
RL   Am. J. Med. Genet. A 167A:2555-2562(2015).
RN   [10]
RP   VARIANTS BPS LEU-189; PRO-496 AND HIS-666.
RX   PubMed=25691407; DOI=10.1002/ajmg.a.36896;
RA   Leslie E.J., O'Sullivan J., Cunningham M.L., Singh A., Goudy S.L.,
RA   Ababneh F., Alsubaie L., Ch'ng G.S., van der Laar I.M., Hoogeboom A.J.,
RA   Dunnwald M., Kapoor S., Jiramongkolchai P., Standley J., Manak J.R.,
RA   Murray J.C., Dixon M.J.;
RT   "Expanding the genetic and phenotypic spectrum of popliteal pterygium
RT   disorders.";
RL   Am. J. Med. Genet. A 167A:545-552(2015).
CC   -!- FUNCTION: Involved in stratified epithelial development. It is a direct
CC       transcriptional target of TP63. Plays a role in NF-kappa-B activation.
CC       {ECO:0000269|PubMed:12446564, ECO:0000269|PubMed:22197488}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- SUBUNIT: Interacts with PRKCB (By similarity). Interacts with TRAF1,
CC       TRAF2, TRAF3 and TRAF5. Interacts with BIRC2/c-IAP1, BIRC3/c-IAP2 and
CC       XIAP/BIRC4. {ECO:0000250, ECO:0000269|PubMed:12446564,
CC       ECO:0000269|PubMed:21931591}.
CC   -!- INTERACTION:
CC       P57078; Q13490: BIRC2; NbExp=3; IntAct=EBI-4422308, EBI-514538;
CC       P57078; Q13489: BIRC3; NbExp=3; IntAct=EBI-4422308, EBI-517709;
CC       P57078; O14641: DVL2; NbExp=4; IntAct=EBI-4422308, EBI-740850;
CC       P57078; Q9NWT6: HIF1AN; NbExp=4; IntAct=EBI-4422308, EBI-745632;
CC       P57078; P98170: XIAP; NbExp=2; IntAct=EBI-4422308, EBI-517127;
CC       P57078-2; Q9Y4H4: GPSM3; NbExp=3; IntAct=EBI-12854608, EBI-347538;
CC       P57078-2; Q99932-2: SPAG8; NbExp=3; IntAct=EBI-12854608, EBI-11959123;
CC       P57078-2; B2RUY7: VWC2L; NbExp=3; IntAct=EBI-12854608, EBI-11747707;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Membrane {ECO:0000250}; Peripheral
CC       membrane protein {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P57078-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P57078-2; Sequence=VSP_004862;
CC   -!- TISSUE SPECIFICITY: Expressed in hair follicles and skin.
CC       {ECO:0000269|PubMed:26129644}.
CC   -!- PTM: May be phosphorylated by MAP3K2 and MAP3K3. {ECO:0000250}.
CC   -!- PTM: Proteolytically cleaved by during Fas-induced apoptosis. Cleavage
CC       at Asp-388 and Asp-426. {ECO:0000269|PubMed:12446564}.
CC   -!- PTM: Polyubiquitinated with 'Lys-48' and 'Lys-63'-linked chains by
CC       BIRC2/c-IAP1 and BIRC3/c-IAP2, leading to activation of NF-kappa-B.
CC       {ECO:0000269|PubMed:21931591}.
CC   -!- DISEASE: Bartsocas-Papas syndrome (BPS) [MIM:263650]: An autosomal
CC       recessive disorder characterized by multiple popliteal pterygia leading
CC       to severe arthrogryposis, ankyloblepharon filiforme adnatum, filiform
CC       bands between the jaws, synostosis of the carpal/tarsal and phalangeal
CC       bones in the hands and feet, digital hypoplasia/aplasia, complete soft-
CC       tissue syndactyly, lack of nails, lack of scalp hair, eyebrows and
CC       eyelashes, blepharophimosis, cleft lip and/or palate, and hypoplastic
CC       external genitalia. Early lethality is common, although survival into
CC       childhood and beyond has been reported. {ECO:0000269|PubMed:22197488,
CC       ECO:0000269|PubMed:22197489, ECO:0000269|PubMed:25691407}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: CHAND syndrome (CHANDS) [MIM:214350]: An autosomal recessive
CC       syndrome characterized by ankyloblepharon, sparse, curly and woolly
CC       hair, nail dysplasia, and oral frenula. {ECO:0000269|PubMed:23610050,
CC       ECO:0000269|PubMed:26129644}. Note=The disease may be caused by
CC       variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB047783; BAB56136.1; -; mRNA.
DR   EMBL; AP001743; BAA95526.1; -; Genomic_DNA.
DR   CCDS; CCDS13675.1; -. [P57078-2]
DR   AlphaFoldDB; P57078; -.
DR   SMR; P57078; -.
DR   DIP; DIP-40722N; -.
DR   IntAct; P57078; 379.
DR   STRING; 9606.ENSP00000332454; -.
DR   BindingDB; P57078; -.
DR   ChEMBL; CHEMBL6083; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; P57078; -.
DR   iPTMnet; P57078; -.
DR   PhosphoSitePlus; P57078; -.
DR   BioMuta; RIPK4; -.
DR   DMDM; 10719883; -.
DR   EPD; P57078; -.
DR   jPOST; P57078; -.
DR   MassIVE; P57078; -.
DR   MaxQB; P57078; -.
DR   PeptideAtlas; P57078; -.
DR   PRIDE; P57078; -.
DR   ProteomicsDB; 56989; -. [P57078-1]
DR   ProteomicsDB; 56990; -. [P57078-2]
DR   Antibodypedia; 9243; 306 antibodies from 26 providers.
DR   Ensembl; ENST00000332512.8; ENSP00000332454.3; ENSG00000183421.12. [P57078-2]
DR   Ensembl; ENST00000352483.3; ENSP00000330161.2; ENSG00000183421.12. [P57078-1]
DR   MANE-Select; ENST00000332512.8; ENSP00000332454.3; NM_020639.3; NP_065690.2. [P57078-2]
DR   UCSC; uc002yzn.2; human. [P57078-1]
DR   GeneCards; RIPK4; -.
DR   HGNC; HGNC:496; RIPK4.
DR   HPA; ENSG00000183421; Tissue enhanced (esophagus).
DR   MalaCards; RIPK4; -.
DR   MIM; 214350; phenotype.
DR   MIM; 263650; phenotype.
DR   MIM; 605706; gene.
DR   neXtProt; NX_P57078; -.
DR   OpenTargets; ENSG00000183421; -.
DR   Orphanet; 1234; Bartsocas-Papas syndrome.
DR   Orphanet; 1401; CHAND syndrome.
DR   VEuPathDB; HostDB:ENSG00000183421; -.
DR   eggNOG; KOG0192; Eukaryota.
DR   eggNOG; KOG0504; Eukaryota.
DR   GeneTree; ENSGT00940000159908; -.
DR   HOGENOM; CLU_015188_0_0_1; -.
DR   InParanoid; P57078; -.
DR   OMA; HSKENTC; -.
DR   PhylomeDB; P57078; -.
DR   TreeFam; TF106506; -.
DR   PathwayCommons; P57078; -.
DR   SignaLink; P57078; -.
DR   ChiTaRS; RIPK4; human.
DR   Pharos; P57078; Tchem.
DR   PRO; PR:P57078; -.
DR   Proteomes; UP000005640; Chromosome 21.
DR   RNAct; P57078; protein.
DR   Bgee; ENSG00000183421; Expressed in esophagus squamous epithelium and 128 other tissues.
DR   Genevisible; P57078; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0002009; P:morphogenesis of an epithelium; IMP:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IEA:InterPro.
DR   Gene3D; 1.25.40.20; -; 3.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF12796; Ank_2; 4.
DR   Pfam; PF13637; Ank_4; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR01415; ANKYRIN.
DR   SMART; SM00248; ANK; 10.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 9.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ANK repeat; ATP-binding; Cytoplasm; Disease variant;
KW   Ectodermal dysplasia; Isopeptide bond; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Receptor; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN           1..832
FT                   /note="Receptor-interacting serine/threonine-protein kinase
FT                   4"
FT                   /id="PRO_0000086613"
FT   DOMAIN          22..286
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REPEAT          485..514
FT                   /note="ANK 1"
FT   REPEAT          518..547
FT                   /note="ANK 2"
FT   REPEAT          551..580
FT                   /note="ANK 3"
FT   REPEAT          584..613
FT                   /note="ANK 4"
FT   REPEAT          617..647
FT                   /note="ANK 5"
FT   REPEAT          651..680
FT                   /note="ANK 6"
FT   REPEAT          684..713
FT                   /note="ANK 7"
FT   REPEAT          717..746
FT                   /note="ANK 8"
FT   REPEAT          750..780
FT                   /note="ANK 9"
FT   REPEAT          782..811
FT                   /note="ANK 10"
FT   REGION          325..368
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          389..424
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        330..355
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        143
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         28..36
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         51
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   SITE            388..389
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000269|PubMed:12446564"
FT   SITE            426..427
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000269|PubMed:12446564"
FT   CROSSLNK        51
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:21931591"
FT   CROSSLNK        145
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:21931591"
FT   VAR_SEQ         278..325
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.1"
FT                   /id="VSP_004862"
FT   VARIANT         12
FT                   /note="A -> G (in dbSNP:rs6586239)"
FT                   /id="VAR_030160"
FT   VARIANT         81
FT                   /note="I -> N (in BPS; dbSNP:rs387906922)"
FT                   /evidence="ECO:0000269|PubMed:22197488"
FT                   /id="VAR_067331"
FT   VARIANT         121
FT                   /note="I -> N (in BPS; loss of function;
FT                   dbSNP:rs387906923)"
FT                   /evidence="ECO:0000269|PubMed:22197489"
FT                   /id="VAR_067332"
FT   VARIANT         163
FT                   /note="G -> D (in CHANDS; unknown pathological
FT                   significance; dbSNP:rs764278537)"
FT                   /evidence="ECO:0000269|PubMed:23610050"
FT                   /id="VAR_081473"
FT   VARIANT         177
FT                   /note="S -> N (in dbSNP:rs12482626)"
FT                   /id="VAR_030161"
FT   VARIANT         184
FT                   /note="T -> I (in BPS; loss of function)"
FT                   /evidence="ECO:0000269|PubMed:22197489"
FT                   /id="VAR_067333"
FT   VARIANT         189
FT                   /note="P -> L (in BPS; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:25691407"
FT                   /id="VAR_085697"
FT   VARIANT         284
FT                   /note="E -> K (in CHANDS; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:26129644"
FT                   /id="VAR_081474"
FT   VARIANT         462
FT                   /note="I -> N (in dbSNP:rs55809511)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041050"
FT   VARIANT         463
FT                   /note="V -> M (in dbSNP:rs55645753)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041051"
FT   VARIANT         496
FT                   /note="A -> P (in BPS; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:25691407"
FT                   /id="VAR_085698"
FT   VARIANT         562
FT                   /note="N -> Y (in dbSNP:rs55829311)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041052"
FT   VARIANT         666
FT                   /note="R -> H (in BPS; unknown pathological significance;
FT                   dbSNP:rs763794698)"
FT                   /evidence="ECO:0000269|PubMed:25691407"
FT                   /id="VAR_085699"
FT   VARIANT         669
FT                   /note="R -> H (in dbSNP:rs56056485)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041053"
FT   VARIANT         749
FT                   /note="P -> S (in dbSNP:rs35537517)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041054"
FT   CONFLICT        714
FT                   /note="M -> V (in Ref. 1; BAB56136)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   832 AA;  91611 MW;  5D8FFFD5F04F7ECB CRC64;
     MEGDGGTPWA LALLRTFDAG EFTGWEKVGS GGFGQVYKVR HVHWKTWLAI KCSPSLHVDD
     RERMELLEEA KKMEMAKFRY ILPVYGICRE PVGLVMEYME TGSLEKLLAS EPLPWDLRFR
     IIHETAVGMN FLHCMAPPLL HLDLKPANIL LDAHYHVKIS DFGLAKCNGL SHSHDLSMDG
     LFGTIAYLPP ERIREKSRLF DTKHDVYSFA IVIWGVLTQK KPFADEKNIL HIMVKVVKGH
     RPELPPVCRA RPRACSHLIR LMQRCWQGDP RVRPTFQGNG LNGELIRQVL AALLPVTGRW
     RSPGEGFRLE SEVIIRVTCP LSSPQEITSE TEDLCEKPDD EVKETAHDLD VKSPPEPRSE
     VVPARLKRAS APTFDNDYSL SELLSQLDSG VSQAVEGPEE LSRSSSESKL PSSGSGKRLS
     GVSSVDSAFS SRGSLSLSFE REPSTSDLGT TDVQKKKLVD AIVSGDTSKL MKILQPQDVD
     LALDSGASLL HLAVEAGQEE CAKWLLLNNA NPNLSNRRGS TPLHMAVERR VRGVVELLLA
     RKISVNAKDE DQWTALHFAA QNGDESSTRL LLEKNASVNE VDFEGRTPMH VACQHGQENI
     VRILLRRGVD VSLQGKDAWL PLHYAAWQGH LPIVKLLAKQ PGVSVNAQTL DGRTPLHLAA
     QRGHYRVARI LIDLCSDVNV CSLLAQTPLH VAAETGHTST ARLLLHRGAG KEAMTSDGYT
     ALHLAARNGH LATVKLLVEE KADVLARGPL NQTALHLAAA HGHSEVVEEL VSADVIDLFD
     EQGLSALHLA AQGRHAQTVE TLLRHGAHIN LQSLKFQGGH GPAATLLRRS KT
//
